A New Dawn in Breast Cancer Treatment: Ultra-Hypofractionated Radiotherapy

By HEOR Staff Writer

December 8, 2023

A Shift in Radiotherapy Practices

Breast cancer treatment often includes radiotherapy. Traditionally, patients in Ireland underwent a moderately hypofractionated regimen, involving 15 sessions over three weeks. Recent clinical trials, however, have explored the efficacy of an ultra-hypofractionated regimen: five sessions over one week, with larger doses per session. Such a shift in practice requires justification by the Health Information and Quality Authority (HIQA) under Irish law, ensuring that the benefits outweigh the risks.

Evidence Review and Expert Input

To justify this practice, HIQA reviewed medical literature and consulted experts, including a patient representative. Considerations included side effects, quality of life, cosmetic outcome, and the effectiveness of ultra-hypofractionated radiotherapy compared to its moderately hypofractionated counterpart. Occupational and public radiation safety issues were also evaluated. The evidence indicates that for suitable patients, ultra-hypofractionated radiotherapy is as effective and safe as the traditional method.

Advantages of Ultra-Hypofractionated Radiotherapy

A significant advantage of ultra-hypofractionated radiotherapy is the reduced hospital visits for patients, from 15 sessions over three weeks to just five sessions over one week. While both regimens have associated side effects, studies indicate no significant differences between them. After reviewing the risks and benefits, HIQA justified the practice of ultra-hypofractionated radiotherapy for breast cancer.

Evidence Synthesis Process

HIQA’s evidence synthesis process involved a targeted search of grey literature sources. They identified twelve guidelines from professional bodies and organisations specific to various countries. They found two key clinical guidelines relevant to their research questions. HIQA used the risk of bias in systematic reviews (ROBIS) tool to appraise the systematic review in the NICE clinical guideline.

In Conclusion

The shift towards ultra-hypofractionated radiotherapy represents a significant advance in breast cancer treatment. The practice not only reduces the treatment burden for patients but also maintains the same level of effectiveness and safety as the traditional approach. As always, the choice of treatment should be tailored to the individual patient’s characteristics, ensuring the best possible outcome.

Reference url

Recent Posts

CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025

By João L. Carapinha

September 11, 2025

Misleading prescription drug ads have become a pressing concern in the United States, prompting decisive federal action. What are the new measures targeting deceptive pharmaceutical advertising, and how will these changes affect public health and healthcare costs? In September 2025, a